RxDoctor Payments DataLook up a doctor →

James Bellor, MD

Rheumatology · Columbia, MDNPI 1710905377

Payments from drug & device makers

$80,104in general payments, 2019–2025

Across 755 payments — averaging $106.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$38K
  • Eli Lilly$29K
  • AbbVie$3K
  • Johnson & Johnson$3K
  • UCB, Inc.$2K
  • Novartis$1K
  • plus $4K from 26 others

What the payments were for

  • Food & beverage$15,92397%
  • Education$4413%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$80,104 in reported general payments places this provider in the 85th percentile of 173 rheumatology providers in Maryland.

See all rheumatology providers in Maryland

Medicare billing

Part B allowed, 2024
$2,492,893
Medicare patients
611
Services billed
122,324

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab34$324,894
Enbrel SureclickEtanercept26$224,149
Xeljanz XrTofacitinib Citrate38$210,929
Cosentyx (2 Syringes)Secukinumab20$198,792
OrenciaAbatacept23$142,219
Humira(Cf)Adalimumab16$122,128
ActemraTocilizumab23$118,003
RinvoqUpadacitinib17$102,213
Humira PenAdalimumab12$81,738
OxycontinOxycodone Hcl35$77,854
RasuvoMethotrexate/Pf20$14,257
Hydroxychloroquine Sulfate190$10,882
MethotrexateMethotrexate Sodium275$10,293
Pregabalin107$5,969
Oxycodone Hcl203$5,092

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieHumira(Cf), Rinvoq$2,992$224,34233 claims
NovartisCosentyx (2 Syringes)$1,102$198,79220 claims
E.r. Squibb & Sons, L.L.C.Orencia$292$142,21923 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 173 rheumatology providers in Maryland.

Other rheumatology in Columbia

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →